Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9054801 | 0.98 | HTR2A (0.40) | HTR2ACHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL13722653 | 0.85 | CHEK1 (0.36) | HTR2ACHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL28005361 | 0.85 | HTR2A (0.34) | HTR2ACHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL15587858 | 0.84 | MAP4K4 (0.41) | HTR2A | |
| SCHEMBL18977639 | 0.82 | POLB (0.42) | — | |
| SCHEMBL19193199 | 0.82 | POLB (0.44) | — | |
| SCHEMBL10177642 | 0.80 | POLB (0.46) | — | |
| SCHEMBL2600249 | 0.80 | HTR2A (0.40) | HTR2ACHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL10120678 | 0.78 | POLB (0.47) | — | |
| Hydrochloric Acid SCHEMBL4521825 | 0.78 | HTR2A (0.39) | HTR2ACHEK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004284-A1 | Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004284-A1 | Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM1, GRIK5 | HTR2A 130/4885CHEK1 3795/4885CCNA2 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.